AbbVie's Upadacitinib Shows Clinical Benefit In Second Late-Stage Ulcerative Colitis Study
- AbbVie Inc (NYSE: ABBV) announces data from the second Phase 3 study, U-ACCOMPLISH, evaluating upadacitinib in patients with moderate to severe ulcerative colitis. The study met the primary and secondary endpoints.
- 33% of patients receiving upadacitinib achieved clinical remission at week eight compared to 4% of patients receiving placebo.
- 74% of upadacitinib-treated patients achieved clinical response at week eight versus 25% of patients receiving placebo on secondary endpoints. At week 2, 63% of patients in the upadacitinib arm achieved clinical response versus 26% in placebo.
- At week 8, 44% of patients treated with upadacitinib achieved endoscopic improvement versus 8% of patients receiving placebo.
- 37% of upadacitinib-treated patients achieved histologic-endoscopic mucosal improvement at week eight compared to 6% patients receiving placebo.
- On the safety front, upadacitinib was safe, with no new safety risks observed.
- AbbVie will present full results from the U-ACCOMPLISH study at a future medical meeting and submitted for publication in a peer-reviewed journal.
- In December last year, the first Phase 3 induction study (U-ACHIEVE) in ulcerative colitis also met its primary endpoint of clinical remission as well as secondary endpoints.
- Last month, RINVOQ (upadacitinib) received the European Commission's approval to treat psoriatic arthritis and ankylosing spondylitis.
- Price Action: ABBV is up 1.81% at $106.91 in market trading hours on the last check Monday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Phase 3 Study ulcerative colitisBiotech News Health Care FDA After-Hours Center General
